Lenapharm(SPRL)

BE 0556.895.014

	2023		2022		2021		2020
Profit/Loss Section 9904: Profit/Loss of the financial year (after taxes on result) (+/-)	€ 5.760	-73%	€ 21.109	373%	€ 4.459	125%	€ -18.023
Equity Section 10/15: Equity consists of capital, capital reserves and earnings that remain within the company. These are fully owned by the company and are at its disposal to cover its risks. The better the ratio between equity and debts, the more solvent a company is. A positive equity ratio is important. A negative equity ratio (because of accumulated losses) is a severe warning sign that the continuity of the company may be threatened.	€ 112.963	5%	€ 107.202	25%	€ 86.093	5%	€ 81.633
Gross margin Section 9900: Gross margin or added value is net sales minus the direct costs of the goods sold. In other words: sales invoices minus purchase invoices (70/74 – 60/61). A negative gross margin is a warning sign especially when occurring over several years. It may indicate that the company has insufficient means to cover internal costs like salaries, etc.	€ 15.966	-58%	€ 37.994	80%	€ 21.049	> 1.000%	€ -245

	Date	Publication
	09-12-2022	Capital, Shares - Resignations, Appointments (FR)
	03-09-2014	Resignations, Appointments (FR)
	30-07-2014	Rubric Constitution (New Juridical Person, Opening Branch, etc...) (FR)

What is the VAT number of Lenapharm?

The VAT number of Lenapharm is BE0556895014.

When was Lenapharm founded?

Lenapharm was founded on 28-07-2014.

What is the address of Lenapharm?

The current registered office of Lenapharm is located at Boulevard Général Jacques 42/1, 1050 Ixelles.

When was the last time Lenapharm filed their annual financial statements?

The most recent financial statements of Lenapharm were filed on 17-10-2024. You can view them here.

How many employees does Lenapharm have?

There are currently no employees working at Lenapharm or no workforce information is available.

What is the annual turnover of Lenapharm?

At the time of its most recent financial statements, Lenapharm did not publish any turnover figures. Lenapharm reported a gross margin of €15,966.02.